-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Ii0qjHUOIiTkKpgr7AJNM3o1SQy3QMHZwQ6rIAMy48ETmNCffm7qB+BJImpDxNwn
 zjV9wP3ulWzkx7WeHH5lWg==

<SEC-DOCUMENT>0001019687-05-002101.txt : 20050802
<SEC-HEADER>0001019687-05-002101.hdr.sgml : 20050802
<ACCEPTANCE-DATETIME>20050802163344
ACCESSION NUMBER:		0001019687-05-002101
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20050801
ITEM INFORMATION:		Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20050802
DATE AS OF CHANGE:		20050802

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21846
		FILM NUMBER:		05992411

	BUSINESS ADDRESS:	
		STREET 1:		7825 FAY AVENUE SUITE 200
		CITY:			LAJOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		2129120930

	MAIL ADDRESS:	
		STREET 1:		7825 FAY AVENUE SUITE 200
		CITY:			LAJOLLA
		STATE:			CA
		ZIP:			92037

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aethlon_8k-080205.txt
<TEXT>
<PAGE>

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934



Date of Report (Date of earliest event reported):   August 1, 2005
                                                    ----------------------------

                              AETHLON MEDICAL, INC.
                              ---------------------
             (Exact name of registrant as specified in its charter)

         Nevada                                                  13-3632859
- ----------------------------                                 -------------------
(State or other jurisdiction                                    (IRS Employer
    of incorporation)                                        Identification No.)

                                     0-21846
                           --------------------------
                            (Commission File Number)

        3030 Bunker Hill Street, Suite 400, San Diego, California 92109
- --------------------------------------------------------------------------------
             (Address of principal executive offices)           (Zip Code)


Registrant's telephone number, including area code:     (858) 459-7800
                                                        -----------------



                                 Not applicable
- --------------------------------------------------------------------------------
         (Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))



<PAGE>


THIS FORM 8-K AND OTHER REPORTS FILED BY AETHLON MEDICAL, INC. (THE "COMPANY")
FROM TIME TO TIME WITH THE SECURITIES AND EXCHANGE COMMISSION (COLLECTIVELY THE
"FILINGS") CONTAIN FORWARD LOOKING STATEMENTS AND INFORMATION THAT ARE BASED
UPON BELIEFS OF, AND INFORMATION CURRENTLY AVAILABLE TO, THE COMPANY'S
MANAGEMENT AS WELL AS ESTIMATES AND ASSUMPTIONS MADE BY THE COMPANY'S
MANAGEMENT. WHEN USED IN THE FILINGS THE WORDS "ANTICIPATE", "BELIEVE",
"ESTIMATE", "EXPECT", "FUTURE", "INTEND", "PLAN" OR THE NEGATIVE OF THESE TERMS
AND SIMILAR EXPRESSIONS AS THEY RELATE TO THE COMPANY'S OR THE COMPANY'S
MANAGEMENT IDENTIFY FORWARD LOOKING STATEMENTS. SUCH STATEMENTS REFLECT THE
CURRENT VIEW OF THE COMPANY WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO
RISKS, UNCERTAINTIES, ASSUMPTIONS AND OTHER FACTORS RELATING TO THE COMPANY'S
INDUSTRY, OPERATIONS AND RESULTS OF OPERATIONS AND ANY BUSINESSES THAT MAY BE
ACQUIRED BY THE COMPANY. SHOULD ONE OR MORE OF THESE RISKS OR UNCERTAINTIES
MATERIALIZE, OR SHOULD THE UNDERLYING ASSUMPTIONS PROVE INCORRECT, ACTUAL
RESULTS MAY DIFFER SIGNIFICANTLY FROM THOSE ANTICIPATED, BELIEVED, ESTIMATED,
EXPECTED, INTENDED OR PLANNED.


ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS;
APPOINTMENT OF PRINCIPAL OFFICERS.

         On August 1, 2005, Mr. Edward C. Hall was terminated as the Company's
Chief Financial Officer ("CFO") as the Company transitions from having a
part-time CFO to a full-time CFO. On August 1, 2005, Mr. James W. Dorst was
appointed as CFO of the Company. Mr. Hall will remain as an advisor to the
Company through August 31, 2005. Mr. Dorst brings close to 20 years of senior
management experience in finance, operations, planning and business transactions
to the Company. Prior to joining Aethlon, Mr. Dorst was Vice President of
Finance and Operations for VerdiSoft Corporation, a developmental-stage
mobile-software developer recently acquired by YAHOO, INC. (NASDAQ: YHOO).
Previously, Mr. Dorst held executive positions as SVP of Finance and
Administration at SeeCommerce; COO/CFO of Omnis Technology Corp (now NASDAQ
Small Cap: RDTA); CFO and SVP of Information Technology at Savoir Technology
Group, Inc. (acquired by NYSE:AVT). Mr. Dorst practiced as a Certified Public
Accountant with Coopers & Lybrand (PricewaterhouseCoopers) and holds an MS in
Accounting and BS in finance from the University of Oregon. Mr. Dorst will
receive a salary of $150,000 per year and stock options to purchase 500,000
shares of the Company's common stock at an exercise price of $0.23 per share
vesting over three years.

         On August 2, 2005, the Company issued a press release announcing the
appointment of Mr. Dorst as the Company's Chief Financial Officer. The full text
of the press release is set forth in Exhibit 99.1 attached hereto and is
incorporated in this Report as if fully set forth herein.


ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits.

         99.1       Press Release dated August 2, 2005



<PAGE>


                                   SIGNATURES

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.



                                              AETHLON MEDICAL, INC.
                                              ----------------------------------
                                              (Registrant)

Date: August 2, 2005
      --------------
                                              By: /s/ James A. Joyce
                                                  ------------------------------
                                                  Name James A. Joyce
                                                  Title: Chief Executive Officer



</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>aethlon_8kex99-1.txt
<TEXT>
<PAGE>
EXHIBIT 99.1

AETHLON MEDICAL, INC.

FOR IMMEDIATE RELEASE:                                Contact:
                                                      Anne Hoversten
                                                      Aethlon Medical, Inc.
                                                      Investor Relations
                                                      858.459.7800 x300
                                                      anne@aethlonmedical.com



                     AETHLON MEDICAL APPOINTS JAMES W. DORST
                           AS CHIEF FINANCIAL OFFICER


San Diego, CA, August 2, 2005 - Aethlon Medical, Inc. (OTCBB:AEMD) announced
today that James W. Dorst has been appointed Chief Financial Officer. Mr. Dorst
brings close to 20 years of senior management experience in finance, operations,
planning and business transactions to the Company. Prior to joining Aethlon, Mr.
Dorst was Vice President of Finance and Operations for VerdiSoft Corporation, a
developmental-stage mobile-software developer recently acquired by YAHOO, INC.
(NASDAQ: YHOO). Previously, Mr. Dorst held executive positions as SVP of Finance
and Administration at SeeCommerce; COO/CFO of Omnis Technology Corp (now NASDAQ
Small Cap: RDTA); CFO and SVP of Information Technology at Savoir Technology
Group, Inc. (acquired by NYSE:AVT). Mr. Dorst practiced as a Certified Public
Accountant with Coopers & Lybrand (PricewaterhouseCoopers) and holds an MS in
Accounting and BS in finance from the University of Oregon.

"The Aethlon family is excited to have an executive of Jim's caliber and
experience joining our team as a full-time CFO," stated Chairman and CEO, James
A. Joyce, "He will play a critical role in the effort to transition our science
from the labs and into the marketplace." Joyce added, "I also want to take this
opportunity to thank Ned Hall for his contribution to our success thus far and
wish him well in future endeavors". Mr. Hall, a principal with Tatum partners,
has acted as CFO since August of 2002.

About Aethlon Medical

Aethlon Medical is pioneering the development of viral filtration devices to
treat drug and vaccine resistant pathogens. The market focus is the treatment of
the Human Immunodeficiency Virus (HIV), Hepatitis-C (HCV), and Biological Weapon
Threats. Aethlon has an experienced management team, which receives support and
guidance from globally recognized science advisors representing the infectious
disease, biowarfare, and dialysis industries. Clinical Trials to treat HIV and
HCV patients in India are scheduled to begin in the coming months, and U.S.
clinical studies are expected to begin later this year. More information on
Aethlon Medical and the Hemopurifier technology is available at
www.aethlonmedical.com.


CERTAIN OF THE STATEMENTS HEREIN MAY BE FORWARD-LOOKING AND INVOLVE RISKS AND
UNCERTAINTIES. SUCH FORWARD-LOOKING STATEMENTS INVOLVE ASSUMPTIONS, KNOWN AND
UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS WHICH MAY CAUSE THE ACTUAL
RESULTS, PERFORMANCE OR ACHIEVEMENTS OF AETHLON MEDICAL, INC TO BE MATERIALLY
DIFFERENT FROM ANY FUTURE RESULTS, PERFORMANCE, OR ACHIEVEMENTS EXPRESSED OR
IMPLIED BY THE FORWARD-LOOKING STATEMENTS. SUCH POTENTIAL RISKS AND
UNCERTAINTIES INCLUDE, WITHOUT LIMITATION, THE COMPANY'S ABILITY TO RAISE
CAPITAL WHEN NEEDED, THE COMPANY'S ABILITY TO COMPLETE THE DEVELOPMENT OF ITS
PLANNED PRODUCTS, THE ABILITY OF THE COMPANY TO OBTAIN FDA AND OTHER REGULATORY
APPROVALS PERMITTING THE SALE OF ITS PRODUCTS, THE COMPANY'S ABILITY TO
MANUFACTURE ITS PRODUCTS AND PROVIDE ITS SERVICES, THE IMPACT OF GOVERNMENT
REGULATIONS, PATENT PROTECTION ON THE COMPANY'S PROPRIETARY TECHNOLOGY, PRODUCT
LIABILITY EXPOSURE, UNCERTAINTY OF MARKET ACCEPTANCE, COMPETITION, TECHNOLOGICAL
CHANGE, AND OTHER RISK FACTORS. IN SUCH INSTANCES, ACTUAL RESULTS COULD DIFFER
MATERIALLY AS A RESULT OF A VARIETY OF FACTORS, INCLUDING THE RISKS ASSOCIATED
WITH THE EFFECT OF CHANGING ECONOMIC CONDITIONS AND OTHER RISK FACTORS DETAILED
IN THE COMPANY'S SECURITIES AND EXCHANGE COMMISSION FILINGS.



</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
